GlassScriptPhysician profile
Rakesh K Passi
NPI 1275550915
$30,315.06
in general payments reported to CMS, 2019-2025
63 companies · $4,599 in 2025
The $4,599 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,404 · 2020: $3,102 · 2021: $5,348 · 2022: $5,178 · 2023: $3,630 · 2024: $4,054 · 2025: $4,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,282.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,534.30 | 2019-2025 | Farxiga, Lokelma, Breztri |
| Boston Scientific Corporation | $2,630.61 | 2019-2025 | Avvigo Guidance System, Wolverine Coronary Cutting Balloon, Guidezilla |
| Janssen Pharmaceuticals, INC | $2,376.94 | 2019-2024 | Xarelto |
| Abbott Laboratories | $1,865.12 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Coroflow, Optis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,501.64 | 2019-2025 | Jardiance, Synjardy |
| Novartis Pharmaceuticals Corporation | $1,499.79 | 2019-2025 | |
| Biotronik INC. | $1,487.40 | 2020-2025 | Biomonitor, Acticor 7 Vr-T Dx, Amvia Edge |
| Abiomed | $1,349.22 | 2019-2025 | Impella |
| E.R. Squibb & Sons, L.L.C. | $1,173.98 | 2019-2025 | Camzyos, Eliquis |
| Cvrx, INC. | $1,152.89 | 2021-2025 | Barostim Neo System |
| Amgen INC. | $759.24 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $702.72 | 2019-2025 | Verquvo, Steglatro, Belsomra |
| Esperion Therapeutics, INC. | $612.91 | 2020-2025 | Nexletol |
| Medtronic, INC. | $501.07 | 2021-2025 | Onyx Frontier, Symplicity G3, Micra |
| Amarin Pharma, INC. | $424.22 | 2019-2023 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rakesh Passi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.